Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million
The company will manufacture a conjugated vaccine candidate being developed to prevent the disease melloidosis.
Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced in a July 7, 2020 press release that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.
In the first program, valued at $8.5 million, the company will manufacture a conjugated vaccine candidate being developed to prevent the disease melloidosis. The candidate, developed at the University of Nevada, Reno, will be tested in a Phase 1 clinical trial. It is made up of the conserved protein from the bacterium Burkholderia pseudomallei and the adjuvant CPS-CRM-197.
In the second program, valued at $4.6 million, the company will manufacture outer membrane vesicles from Burkholderia mallei as a potential vaccine against the bacterial disease glanders. The vaccine candidate was developed at Tulane University, and the material will support a Phase 1 clinical trial.
In the third program, valued at $3.2 million, the company will manufacture a DNA vaccine against Venezuelan equine encephalitis to support a Phase 1 clinical trial. The vaccine was developed at the United States Army Medical Research Institute of Infectious Diseases.
Source: Ology Bioservices
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
